In recent years, with the progress of tumor immunotherapy and gene modification technology, chimeric antigen receptor T cells(CAR-T) has become a hot topic in drug research and development. CAR-T drugs targeting CD19 have significant therapeutic effects on acute lymphoblastic leukemia(ALL) in children, especially relapsed/refractory ALL with poor efficacy of conventional methods such as chemotherapy and hematopoietic stem cell transplantation. Several CAR-T products have been approved by drug regulatory administration for marketing, but no CAR-T products for children with ALL have been approved in China. This study mainly introduces the current situation of CAR-T products licensed to carry out drug clinical trials in China. Then the clinical needs and the critical elements of drug clinical research and development for acute B-cell lymphocytic leukemia in children is discussed, to provide reference for the design of registered clinical trials of similar products.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |